Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 9.435 | 10.4589291653 | 90.21 | 102.33 | 87.4 | 796222 | 95.31923736 | CS |
| 4 | 22.835 | 29.7292019268 | 76.81 | 102.33 | 74.43 | 1448238 | 89.69211659 | CS |
| 12 | 4.765 | 5.02213322091 | 94.88 | 102.33 | 68.8483 | 914025 | 87.41156643 | CS |
| 26 | 61.205 | 159.222164412 | 38.44 | 102.33 | 36.705 | 971722 | 76.21781321 | CS |
| 52 | 81.235 | 441.254752852 | 18.41 | 102.33 | 18.08 | 794872 | 59.57137646 | CS |
| 156 | 89.245 | 858.125 | 10.4 | 102.33 | 6.58 | 408258 | 48.19127182 | CS |
| 260 | 89.245 | 858.125 | 10.4 | 102.33 | 6.58 | 408258 | 48.19127182 | CS |
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。